Ignite Creation Date:
2025-12-24 @ 1:33 PM
Ignite Modification Date:
2026-01-03 @ 8:39 PM
Study NCT ID:
NCT03086395
Status:
WITHDRAWN
Last Update Posted:
2017-03-22
First Post:
2017-03-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Sponsor:
Case Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-04-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2018-01-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2021-01-01
Completion Date Type:
ESTIMATED
First Submit Date:
2017-03-16
First Submit QC Date:
None
Study First Post Date:
2017-03-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-03-16
Last Update Post Date:
2017-03-22
Last Update Post Date Type:
ACTUAL